Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 1,835 0.85%
03 Jun - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

Website BSE NSE
  • Market Cap ₹ 19,164 Cr.
  • Current Price ₹ 1,835
  • High / Low ₹ 2,664 / 1,327
  • Stock P/E 51.6
  • Book Value ₹ 173
  • Dividend Yield 0.48 %
  • ROCE 29.5 %
  • ROE 22.3 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 19.6% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 29.9%

Cons

  • Stock is trading at 10.6 times its book value
  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
181 159 241 273 195 262 241 319 216 310 244 430
116 121 131 146 123 147 135 187 135 176 146 241
Operating Profit 65 37 110 127 72 116 106 132 81 134 98 189
OPM % 36% 24% 46% 47% 37% 44% 44% 41% 38% 43% 40% 44%
14 6 9 12 13 8 11 11 12 10 17 9
Interest 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 14 13 14 14 13 13 14 14 13 13 13 15
Profit before tax 64 30 105 124 71 110 103 129 80 130 101 184
Tax % 23% 26% 26% 26% 23% 26% 25% 26% 25% 27% 25% 24%
49 22 77 91 54 81 78 95 60 96 76 140
EPS in Rs 51.79 2.10 7.40 8.75 5.21 7.74 7.41 9.08 5.70 9.15 7.26 13.42
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
512 616 713 853 1,017 1,200
308 289 443 509 585 695
Operating Profit 205 327 270 344 432 505
OPM % 40% 53% 38% 40% 42% 42%
32 14 23 37 37 44
Interest 1 1 6 5 3 1
Depreciation 21 28 50 54 54 54
Profit before tax 214 313 238 322 413 495
Tax % 21% 25% 26% 25% 25% 25%
169 235 175 240 308 372
EPS in Rs 177.81 247.44 183.93 22.95 29.45 35.52
Dividend Payout % 22% 0% 3% 30% 30% 30%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 19%
TTM: 18%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: 30%
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 27%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 21%
Last Year: 22%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 10 10 10 10 10 10
Reserves 761 990 1,094 1,280 1,516 1,802
52 86 62 32 10 3
118 97 147 192 164 219
Total Liabilities 941 1,183 1,313 1,514 1,701 2,034
240 546 573 593 575 796
CWIP 141 18 74 173 211 50
Investments 199 141 74 137 246 335
361 477 592 611 668 854
Total Assets 941 1,183 1,313 1,514 1,701 2,034

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
155 207 246 265 245
-114 -112 -158 -155 -160
-43 -100 -85 -99 -99
Net Cash Flow -1 -4 3 12 -14

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 131 105 119 117 125 159
Inventory Days 312 503 434 430 331 286
Days Payable 201 152 185 190 150 135
Cash Conversion Cycle 242 456 368 357 306 310
Working Capital Days 160 180 177 163 169 290
ROCE % 32% 21% 26% 28% 30%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08%
7.30% 7.00% 6.49% 7.11% 8.10% 8.33% 9.35%
8.12% 8.40% 8.41% 10.35% 9.82% 9.65% 9.16%
40.50% 40.52% 41.03% 38.46% 38.02% 37.93% 37.41%
No. of Shareholders 1,00,92787,48683,29680,73784,29882,00481,219

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls